| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 3,071 | 3,157 | 3,250 | 3,417 | 4,144 | 4,424 | 4,243 | 4,511 | 4,209 | 3,839 | 3,952 | 3,929 | 4,125 | 3,960 | 4,122 | 3,872 | 3,922 | 3,922 | 4,007 | 3,844 | 4,084 | 3,513 | 3,807 | 3,939 | 3,808 | 4,265 | 4,076 | 4,122 | 3,880 | 3,610 | 4,106 | 4,263 | 4,368 | 4,765 | 4,980 | 5,109 | 4,924 | 5,582 | 5,539 | 5,672 | 5,619 | 6,243 | 6,921 | 7,215 |
| Expenses | 2,289 | 2,331 | 2,667 | 2,702 | 2,883 | 3,157 | 3,260 | 3,264 | 3,472 | 3,104 | 3,099 | 3,287 | 4,789 | 3,329 | 3,401 | 3,608 | 3,107 | 3,131 | 3,788 | 3,629 | 3,320 | 3,040 | 3,254 | 3,239 | 3,066 | 3,306 | 5,415 | 3,791 | 3,615 | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,160 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 5,332 |
| EBITDA | 783 | 825 | 583 | 715 | 1,261 | 1,268 | 983 | 1,246 | 737 | 735 | 853 | 642 | -665 | 631 | 721 | 264 | 814 | 791 | 219 | 215 | 763 | 473 | 553 | 700 | 742 | 960 | -1,339 | 331 | 265 | 98 | 414 | 473 | 515 | 807 | 859 | 950 | 960 | 1,223 | 1,207 | 1,261 | 1,273 | 1,702 | 2,215 | 1,883 |
| Operating Profit % | 25 % | 24 % | 16 % | 19 % | 30 % | 27 % | 23 % | 26 % | 17 % | 18 % | 20 % | 16 % | -20 % | 12 % | 13 % | 6 % | 18 % | 18 % | 1 % | 2 % | 12 % | 12 % | 14 % | 17 % | 18 % | 22 % | -35 % | 7 % | 6 % | 3 % | 10 % | 11 % | 11 % | 17 % | 17 % | 18 % | 19 % | 21 % | 21 % | 21 % | 22 % | 26 % | 31 % | 25 % |
| Depreciation | 107 | 101 | 116 | 122 | 149 | 203 | 211 | 231 | 267 | 261 | 272 | 280 | 273 | 259 | 266 | 219 | 219 | 250 | 253 | 253 | 214 | 215 | 213 | 244 | 216 | 209 | 919 | 203 | 327 | 193 | 204 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 272 | 393 | 299 | 317 | 313 |
| Interest | 3 | 7 | 24 | 10 | 31 | 35 | 29 | 48 | 41 | 44 | 48 | 54 | 59 | 69 | 74 | 79 | 84 | 84 | 83 | 89 | 107 | 44 | 34 | 31 | 32 | 34 | 34 | 33 | 42 | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 |
| Profit Before Tax | 697 | 792 | 581 | 781 | 1,170 | 1,156 | 822 | 1,045 | 520 | 494 | 611 | 383 | -941 | 384 | 441 | 93 | 591 | 518 | -54 | -73 | 496 | 273 | 360 | 525 | 518 | 751 | -2,205 | 167 | -85 | 2 | 210 | 246 | 259 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 |
| Tax | 136 | 224 | 158 | 255 | 417 | 273 | 159 | 410 | 137 | 137 | 154 | 161 | -163 | 181 | 173 | 245 | 294 | 216 | 70 | 767 | 105 | 164 | 147 | 84 | 54 | 202 | -110 | -382 | 427 | 89 | 75 | 89 | 16 | 106 | 134 | 117 | 130 | 188 | 195 | 212 | 114 | 194 | 522 | 342 |
| Net Profit | 561 | 568 | 422 | 526 | 753 | 883 | 663 | 636 | 384 | 357 | 457 | 222 | -778 | 203 | 269 | -152 | 296 | 303 | -123 | -840 | 391 | 109 | 214 | 441 | 464 | 548 | -2,095 | 549 | -512 | -87 | 135 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 860 | 859 | 782 | 1,222 | 1,485 | 1,181 |
| EPS in ₹ | 12.17 | 12.65 | 9.34 | 11.67 | 16.63 | 19.57 | 14.69 | 14.04 | 8.42 | 7.93 | 10.07 | 4.91 | -17.33 | 6.40 | 5.88 | -3.37 | 6.55 | 6.69 | -2.72 | -18.56 | 8.64 | 2.36 | 4.66 | 9.67 | 10.15 | 11.96 | -46.22 | 12.01 | -11.40 | -1.96 | 2.85 | 3.38 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.70 | 18.75 | 16.93 | 26.70 | 32.36 | 25.74 |
Lupin
Lupin
2,316.10
+20.00
(0.87%)
Market Cap
1,05,855.78 Cr
PE Ratio
22.48
Volume
3,13,086.00
Day High - Low
2,341.00 - 2,296.20
52W High-Low
2,381.00 - 1,836.80
Key Fundamentals
Market Cap
1,05,855.78 Cr
EPS
71.95
PE Ratio
22.48
PB Ratio
5.35
Book Value
429.43
EBITDA
5,479.10
Dividend Yield
0.52 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
19.12
Debt to Equity
0.27
Analyst Rating and Forecast
- By Refinitiv from35 analysts
Actual
Company News
View All News
Lupin Limited announces earnings call for Q4 FY26 scheduled on May 8, 2026 at 16:00 hrs IST via Zoom platform. Company complies with SEBI Listing Regulations for quarterly disclosure.
Lupin Limited announces board meeting on May 7, 2026 to approve Q4FY26 audited financial results and consider dividend recommendations. Trading window closed from April 1-May 10, 2026.
Lupin Limited announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States following FDA approval as bioequivalent to Xigduo XR.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,730.20 | #1 4,15,132.94 | 35.49 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 33.27 | |
6,470.00 | 1,71,758.17 | 68.10 | 9,712.00 | 18.67 | 2,191 | -1.02 | 63.24 | |
4,214.60 | 1,42,641.22 | 61.31 | 11,539.40 | 6.99 | 1,911 | 26.24 | 45.65 | |
1,331.20 | 1,11,107.68 | 19.89 | 33,741.20 | 16.73 | 5,725 | -15.28 | 61.94 | |
1,314.70 | 1,06,198.93 | 23.07 | 28,409.50 | 7.12 | 5,291 | -57.18 | 60.61 | |
2,316.10 | #6 1,05,855.78 | #3 22.48 | #6 22,909.50 | #5 13.74 | #6 3,306 | #1 37.44 | 47.90 | |
947.90 | 95,380.92 | #1 18.56 | 23,511.00 | 18.55 | 4,615 | -0.32 | 55.15 | |
2,284.90 | 94,321.83 | 51.90 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 67.86 | |
1,418.70 | 82,398.33 | 23.56 | 32,345.60 | 9.43 | 3,484 | 7.59 | 66.95 | |
2,305.70 | 65,067.04 | 60.89 | 13,435.50 | 6.18 | 1,047 | 15.86 | 63.32 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
13.74 %
Net Income Growth
70.82 %
Cash Flow Change
-17.77 %
ROE
41.95 %
ROCE
20.69 %
EBITDA Margin (Avg.)
22.54 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 |
| Fixed Assets | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 |
| Current Assets | 7,832 | 9,887 | 11,953 | 12,210 | 13,854 | 15,413 | 13,986 | 12,458 | 12,451 | 13,448 | 16,799 |
| Capital Work in Progress | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 |
| Investments | 1,656 | 16 | 2,136 | 262 | 2,296 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 |
| Other Assets | 6,538 | 11,189 | 11,305 | 13,084 | 12,928 | 13,732 | 12,209 | 12,393 | 12,846 | 13,272 | 17,823 |
| Total Equity & Liabilities | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 |
| Current Liabilities | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,498 | 9,265 | 8,502 | 8,961 |
| Non Current Liabilities | 510 | 6,368 | 6,955 | 7,593 | 8,030 | 3,178 | 1,316 | 1,101 | 1,148 | 1,122 | 2,949 |
| Total Equity | 8,898 | 11,196 | 13,532 | 13,617 | 13,789 | 12,581 | 13,858 | 12,222 | 12,543 | 14,374 | 17,294 |
| Reserve & Surplus | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 |
| Share Capital | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 | 560 |
| Investing Activities | -1,034 | -6,769 | -2,527 | 470 | -3,283 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 | -4,172 |
| Operating Activities | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | 3,000 |
| Financing Activities | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 | 1,732 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
| Promoter | 46.86 % | 46.84 % | 46.83 % | 46.81 % | 46.78 % | 47.10 % | 47.11 % | 47.10 % | 47.08 % | 47.07 % | 47.05 % | 47.04 % | 47.01 % | 46.98 % | 46.96 % | 46.95 % | 46.92 % | 46.90 % | 46.90 % | 46.89 % | 46.86 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.11 % | 18.28 % | 19.32 % | 21.50 % | 22.04 % | 21.46 % | 21.25 % | 20.49 % | 21.49 % | 21.71 % |
| DIIs | 22.08 % | 21.68 % | 24.38 % | 24.76 % | 26.84 % | 26.82 % | 27.54 % | 29.38 % | 29.21 % | 28.98 % | 29.42 % | 29.73 % | 27.76 % | 26.78 % | 25.09 % | 24.74 % | 25.41 % | 25.56 % | 26.55 % | 25.58 % | 25.32 % |
| Government | 0.29 % | 0.28 % | 0.28 % | 0.28 % | 0.29 % | 0.29 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.00 % |
| Public / Retail | 10.02 % | 9.91 % | 10.18 % | 9.99 % | 8.53 % | 8.59 % | 8.41 % | 8.06 % | 7.86 % | 7.06 % | 6.24 % | 5.87 % | 5.70 % | 5.65 % | 5.29 % | 5.17 % | 5.10 % | 5.23 % | 5.12 % | 5.10 % | 5.05 % |
| Others | 20.75 % | 21.29 % | 18.34 % | 18.16 % | 17.57 % | 17.19 % | 16.94 % | 15.45 % | 15.85 % | 16.89 % | 17.27 % | 1.23 % | 1.23 % | 1.26 % | 1.15 % | 1.10 % | 1.10 % | 1.05 % | 0.94 % | 0.93 % | 1.06 % |
| No of Share Holders | 0 | 2,93,782 | 3,02,292 | 3,61,288 | 3,61,862 | 3,78,547 | 3,82,828 | 3,78,011 | 3,60,677 | 3,22,678 | 2,89,074 | 2,81,542 | 2,80,248 | 2,88,537 | 2,79,280 | 2,81,988 | 2,83,210 | 2,86,604 | 2,80,256 | 2,88,931 | 2,90,411 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 7.5 | 5 | 5 | 6 | 6.5 | 4 | 4 | 8 | 12 | 0.00 |
| Dividend Yield (%) | 1.02 | 0.68 | 0.85 | 0.59 | 0.87 | 0.61 | 0.25 | 0.39 | 0.52 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 07 May 2026 |  Quarterly Result Announcement | NA | 07 May 2026 | 2,311.50 | 2,296.10 |
| 28 Jul 2021 |  Dividend | ₹ 6.50 /share | 27 Jul 2021 | 1,212.25 | 1,111.60 |
| 15 Jul 2022 | Dividend | ₹ 4.00 /share | 14 Jul 2022 | 683.30 | 643.20 |
| 14 Jul 2023 | Dividend | ₹ 4.00 /share | 14 Jul 2023 | 732.25 | 930.75 |
| 16 Jul 2024 | Dividend | ₹ 8.00 /share | 16 Jul 2024 | 1,655.25 | 1,832.10 |
| 02 Aug 2024 |  Annual General Meeting | NA | 02 Aug 2024 | 1,778.90 | 1,953.55 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 2,151.95 | 2,166.05 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 2,134.25 | 2,169.40 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 2,107.70 | 2,063.00 |
| 25 Jul 2025 | Dividend | ₹ 12.00 /share | 25 Jul 2025 | 2,063.00 | 1,943.40 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 1,930.85 | 1,882.20 |
| 11 Aug 2025 | Annual General Meeting | NA | 11 Aug 2025 | 1,894.70 | 1,918.00 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 1,943.35 | 1,997.00 |
| 12 Feb 2026 | Quarterly Result Announcement | NA | 12 Feb 2026 | 2,150.50 | 2,209.10 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 days ago
3 days agoBoard Meeting Intimation for Considering And Approving The Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31 2026 And Recommend Dividend If Any.4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoU.S. FDA Has Concluded An Inspection At The Companys Manufacturing Facility Located In Somerset New Jersey U.S.A.8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Acquisition9 days ago
9 days agoSettlement Agreement.10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 10, 2026
Apr 10, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 09, 2026
Apr 09, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 08, 2026
Apr 08, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2026
Apr 07, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 07, 2026
Apr 07, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 06, 2026
Apr 06, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 02, 2026
Apr 02, 2026Acquisition Of Minority Shareholding In Multicare Pharmaceuticals Philippines Inc.Apr 01, 2026
Apr 01, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 01, 2026
Apr 01, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 31, 2026
Mar 31, 2026Buyback Of Shares By Multicare Pharmaceuticals Philippines Inc. A Subsidiary Company.Mar 30, 2026
Mar 30, 2026Closure of Trading WindowMar 25, 2026
Mar 25, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 25, 2026
Mar 25, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 24, 2026
Mar 24, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 19, 2026
Mar 19, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 17, 2026
Mar 17, 2026U.S. FDA Has Concluded An Inspection At Our Manufacturing Facility At Ankleshwar India.Mar 07, 2026
Mar 07, 2026Newspaper Publication For The Information Regarding Special Window For Transfer And Dematerialization Of Physical Shares.Mar 07, 2026
Mar 07, 2026Disclosure Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Mar 02, 2026
Mar 02, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionFeb 27, 2026
Feb 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2026
Feb 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Feb 26, 2026
Feb 26, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Feb 26, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 26, 2026
Feb 26, 2026Disclosure Pursuant To Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 25, 2026
Feb 25, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 23, 2026
Feb 23, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2026
Feb 19, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 17, 2026
Feb 17, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 16, 2026
Feb 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2026
Feb 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 13, 2026
Feb 13, 2026 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 13, 2026
Feb 13, 2026Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2026
Feb 12, 2026Board Meeting Outcome for Outcome Of The Board Meeting For Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.Feb 12, 2026
Feb 12, 2026Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.Feb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2026
Feb 10, 2026Settlement And License AgreementFeb 10, 2026
Feb 10, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 09, 2026
Feb 09, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2026
Feb 04, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 47.90
ATR(14)
Volatile 54.89
STOCH(9,6)
Neutral 57.30
STOCH RSI(14)
Neutral 43.56
MACD(12,26)
Bearish -2.36
ADX(14)
Weak Trend 9.67
UO(9)
Bearish 54.73
ROC(12)
Downtrend And Accelerating -0.10
WillR(14)
Neutral -57.29
About Lupin
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The...more
Website
Chairperson NameM D Gupta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
